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A B S T R A C T
PCSK9 inhibition is a novel approach for cholesterol reduction because of its crucial patho-
physiological role in cholesterol metabolism. This work aimed at evaluating whether lupin
protein/peptides may modulate PCSK9 production. Mild hypercholesterolaemic subjects con-
sumed lupin protein or casein (30 g/day) for 4 weeks. The final level of circulating PCSK9,
measured by ELISA, was reduced by 8.5% (p = 0.0454) versus baseline value, whereas it re-
mained unchanged in the control group (casein). For investigating the mechanism of action,
HepG2 cells were treated with peptic and tryptic peptides from lupin protein: reductions
of PCSK9 production and secretion were observed as well as a decrease of hepatic nuclear
factor 1-alpha (HNF1-alpha). For the first time, this work provides evidences that lupin protein/
peptides may modulate the PCSK9 protein level production and secretion, contributing to
explain the beneficial effects observed in animal and human studies and opening a com-
pletely new area of investigation on plant proteins.
© 2016 Elsevier Ltd. All rights reserved.
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1. Introduction
Proprotein convertase (PC) subtilisin/kexintype 9 (PCSK9) is pri-
marily synthesised in the liver and small intestine (Benjannet
et al., 2004). After intracellular autocatalytic cleavage of its
prodomain, mature PCSK9 is secreted from liver cells (McNutt,
Lagace, & Horton, 2007). Animal studies have shown that the
PCSK9 binding to the low density lipoprotein (LDL) receptor
(LDLR) targets the receptor for lysosomal degradation, thereby
providing a possible mechanism through which PCSK9 may
affect cholesterol metabolism (Lo Surdo et al., 2011). In the
absence of PCSK9, the hepatic LDLR is shuttled back to the
plasma membrane after cholesterol delivery to the lysosome
for degradation. PCSK9 binding, instead, prevents this LDLR
shuttling and targets it for degradation (Lagace et al., 2006).
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PCSK9 primarily acts on the LDLR as a circulating plasma
protein and several small-scale studies have shown a posi-
tive relationship between circulating PCSK9 and LDL cholesterol
(LDL-C) levels (Lambert, Sjouke, Choque, Kastelein, & Hovingh,
2012).
High levels of circulating LDL-C accelerate the progression
of atherosclerosis and LDL-C lowering is currently consid-
ered the most effective strategy in preventing coronary artery
disease. Several recent studies have correlated the novel target
PCSK9 with parameters directly related to atherosclerosis pro-
gression (Giunzioni & Tavori, 2015; Gu & Zhang, 2015; Stein &
Raal, 2015; Zhang et al., 2015). The role of circulating PCSK9
in promoting hypercholesterolaemia is beyond dispute and
strongly supported by preclinical experiments and clinical trials,
where antibodies directed against the LDLR binding site in
PCSK9 have effectively reduced LDL-C levels (Roth, McKenney,
Hanotin, Asset, & Stein, 2012; Stein et al., 2012).
Although specific drugs, such as statin, are the main solu-
tion for the treatment of hypercholesterolaemia, a number of
new pharmacological approaches based on the inhibition of
PCSK9 function are currently under development (Lambert et al.,
2012; Verbeek, Stoekenbroek, & Hovingh, 2015). In this sce-
nario, also natural compounds may have an important
preventive role. An example is berberine (Kong et al., 2004), an
isoquinoline alkaloid found in the leaves of some species of
the genus Berberis, which inhibits the progression of
hypercholesterolaemia targeting PCSK9 (Cameron, Ranheim,
Kulseth, Leren, & Berge, 2008).
Lupin is a grain legume cultivated as a sustainable crop in
many countries either for animal or human nutrition.The in-
terest for this seed relies mostly on its high protein content
(35–40%).Besides its useful nutritional features, in the last decade
numerous investigations have shown that lupin provides in-
teresting health benefits (Arnoldi, Boschin, Zanoni, & Lammi,
2015),particularly in theareaofhyperglycaemia control (Bertoglio
et al., 2011; Duranti, Consonni, Magni, Sessa, & Scarafoni, 2008;
Lovati et al., 2012), hypertension prevention (Boschin et al., 2014;
Lee et al., 2009), and cholesterol reduction (Bähr, Fechner,
Kiehntopf, & Jahreis, 2015; Marchesi et al., 2008; Sirtori et al.,
2004, 2012; Weisse et al., 2010). The protein seems to be rel-
evant in these beneficial effects (Arnoldi et al., 2015).
In the framework of the European project Bioprofibre, some
years ago, we have performed a double-blind randomised clini-
cal trial for evaluating the potential hypocholesterolaemic
effects of some legume proteins, including lupin protein, versus
casein as control protein in mild hypercholesterolaemic pa-
tients (Sirtori et al., 2012).This intervention study had a parallel
design and was 4 weeks long.The consumption of the dietary
bar containing lupin protein (30 g/day) resulted in a signifi-
cant reduction of total cholesterol (−11.6 mg/dl = −4.2%, p < 0.05),
whereas no significant cholesterol changes were observed in
the subjects consuming the control bars containing casein.
Further studies were dedicated to elucidate the mecha-
nism of action, mainly working on peptides. In particular, we
have demonstrated that tryptic and peptic peptides derived
from lupin protein are able to interfere with 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMGCoAR) activity, up-
regulating the LDLR and sterol regulatory element binding
proteins 2 (SREBP-2), and increasing the LDL-uptake in HepG2
cells (Lammi, Zanoni, Scigliuolo, D’Amato, & Arnoldi, 2014).
These results suggested the possibility that lupin protein
may also influence the expression of PCSK9. In order to achieve
a rapid confirmation of this hypothesis, we decided to measure
the level of circulating PCSK9 in the plasma of the subjects of
the clinical study described above (Sirtori et al., 2012).The posi-
tive results of this preliminary experiment prompted us to
undertake an extensive in vitro investigation on the mecha-
nism of action through which peptic and tryptic peptides from
lupin protein modulate PCSK9 production by targeting its in-
tracellular processing. This mechanistic study was performed
using human hepatic HepG2 cells as model system, since he-
patocytes are themain source of circulating PCSK9 (Lagace et al.,
2006). The same cellular model had been already used by us
to characterise the hypocholesterolaemic effects of lupin pep-
tides (Lammi et al., 2014), since it also expresses high levels
of LDLR (Tavori et al., 2013).
2. Materials and methods
2.1. Chemicals
Dulbecco’s modified Eagle’s medium (DMEM), L-glutamine,
foetal bovine serum (FBS), phosphate buffered saline (PBS),
penicillin/streptomycin, chemiluminescent reagent, and 96-
well plates were purchased from Euroclone (Milan, Italy). Bovine
serum albumin (BSA), RIPA buffer, and the antibody against
β-actin were bought from Sigma-Aldrich (St. Louis, MO, USA).
The antibody against PCSK9 and HNF1-alpha were bought from
GeneTex (Irvine, CA, USA). The antibodies against rabbit Ig-
HRP,mouse Ig-HRP, phenylmethanesulfonyl fluoride (PMSF), Na-
orthovanadate inhibitors were purchased from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA); the inhibitor cock-
tail Complete Midi was purchased from Roche (Basel, Swiss).
Mini protean TGX pre-cast gel 7.5% and Mini nitrocellulose
Transfer Packs were purchased from BioRad (Hercules, CA, USA).
The Human Proprotein Convertase 9 Immunoassay (Quantikine
ELISA) was bought from R&D System (Minneapolis, MN, USA).
2.2. Brief description of protocol of Bioprofibre clinical
study and quantification of PCSK9 by ELISA in the subject
plasma
The complete protocol of the clinical study and details of the
ethical approval are described in a previous paper (Sirtori et al.,
2012). Briefly, participants were recruited at the University Center
for Dyslipidaemias of the Niguarda Hospital (Milano, Italy), ac-
cording to the following criteria: (i) males and postmenopausal
females; (ii) participants in primary prevention, non-diabetics;
(iii) total cholesterol >220 mg/dL and triglycerides < 200 mg/
dL. A randomised, double-blind, parallel group design was
followed, with total cholesterol as main endpoint. All the can-
didates underwent a stabilisation period on a hypolipidaemic
dietary regimen for 4 weeks. The selected subjects were then
randomised into the dietary treatment groups: each group
consumed for 4 weeks two bars per day containing 30 g the
specific protein source, i.e. casein (control) or a lupin protein
isolate prepared by the Fraunhofer Institute IVV (Freising,
Germany). At the starting and final visits, blood samples were
231J o u rna l o f Func t i ona l F ood s 2 3 ( 2 0 1 6 ) 2 3 0 – 2 4 0
collected after an overnight fast. Both serum and
ethylenediaminetetraacetic acid (EDTA) plasma were pre-
pared by low-speed centrifugation at 4 °C and stored at −80 °C.
Plasma total cholesterol, triacylglycerols, and HDL-cholesterol
(HDL-C) were determined with standard enzymatic tech-
niques (Roche Diagnostics) on a Roche Diagnostics Cobas
400 Analyzer. Plasma LDL-C was calculated with the
Friedewald’s formula. For measuring PCSK9, aliquots of the
plasma samples were 20-fold diluted with Calibrator diluent
RD5P (provided by the ELISA kit of R&D System, Minneapolis,
MN, USA). The experiments were carried out at 37 °C follow-
ing the manufacturer’s instructions. Before starting the assay,
human PCSK9 standards (20.0, 10.0, 5.0, 2.5, 1.25, and 0.625 ng/
mL) were prepared from the stock solution PCSK9 Standard
(40 ng/mL) with serial dilutions (for building the standard curve)
and meanwhile 100 µL the Assay Diluent RD1-9 (provided into
the kit) were added to each wells. Afterward, standards and
samples (50 µL) were pipetted into the wells and the ELISA plate
was allowed to incubate for 2 h at RT. Subsequently, wells were
washed 4 times withWash Buffer, and 200 µL of human PCSK9
Conjugate (HRP-labelled anti-PCSK9) was added to each well
for a 2 h incubation at RT. Following aspiration, wells were
washed 4 times withWash Buffer provided by the kit. After the
last wash, 200 µL of Substrate Solution was added to the wells
and allowed to incubate for 30 min at RT. The reaction was
stopped with 50 µL of Stop Solution (2 N sulphuric acid) and
the absorbance at 450 nm was measured using Synergy H1
(Biotek, Bad Friedrichshall, Germany). The lower limit of de-
tection was 0.096 ng/mL.
2.3. Preparation and analysis of the pepsin and trypsin
peptide mixtures
White lupin seeds (Lupinus albus cultivar Ares) were provided
byTerrena (Matrignè-Ferchaud, France).The total protein extract
was obtained and analysed as previously reported (Lammi et al.,
2014). In brief, proteins were extracted from defatted flour with
100 mMTris-HCl/0.5 M NaCl buffer, pH 8.2 for 2 h at 4 °C. After
centrifugation at 6500 g, for 20 min at 4 °C, the supernatant was
dialysed against 100 mMTris-HCl buffer pH 8.2 for 24 h at 4 °C.
After assessing the protein concentration by Bradford assay,
the total protein extract was dissolved inTris-HCl buffer 100mM
at pH 8, then the pH was adjusted to the optimal hydrolysis
conditions for each enzyme (pH = 2 for pepsin and = 8 for
trypsin) by adding 1 M NaOH or 1 M HCl. After 18 h incuba-
tion and enzyme inactivation, the mixtures were ultra-
filtered through 3000 Da cut-off centrifuge filters (Amicon Ultra-
0.5, Millipore, Billerica, MA, USA) at 12,000 g for 30 min at 4 °C.
The analyses were conducted on a nano-chromatographic
system, UltiMate 3000 RSLCnano System (Thermo Scientific,
Waltham, MA, USA). The peptide mixtures were loaded on a
reversed-phase trap column (Acclaim PepMap100, C18, 100 Å,
100 µm i.d. × 2 cm,Thermo Scientific) for the cleanup and pre-
concentration, then separated on fused silica reverse-phase
column (picoFrit column, C18, 2.7 µm, New Objective), eluting
with a 30 min gradient from 4% buffer A (2% acetonitrile and
0.1% formic acid in water) to 60% buffer B (2% water and 0.1%
formic acid in acetonitrile) at a constant flow rate of 300 nL/
min. The chromatographic column was connected to a LTQ-
XL mass spectrometer (Thermo Scientific) equipped with a
nano-spray ion source. Full scan mass spectra were acquired
in the mass range from m/z 350 to 2000 Da and the five most
intense ions were automatically selected and fragmented in
the ion trap. The results of the analysis are reported in detail
in a previous paper (Lammi et al., 2014).
2.4. Cell line culture
HepG2 cell line was bought from ATCC (HB-8065, ATCC from
LGC Standards, Milan, Italy). The HepG2 cell line was cul-
tured in DMEM high glucose with stable L-glutamine
supplemented with 10% FBS, 100 U/mL penicillin, 100 µg/mL
streptomycin (complete growthmedium) and incubated at 37 °C
under 5% CO2 atmosphere. HepG2 cells were used for no more
than 20 passages after thawing, because the increase of the
number of passages may change the cell characteristics and
impair assay results.
2.5. Western blot analysis
1.5 × 105 HepG2 cells/well (24-well plate) were treated with 1.0
and 2.5 mg/mL of peptic and 0.5 and 1.0 mg/mL of tryptic pep-
tides for 24 h. After each treatment, the medium of each well
was collected in an ice-cold microcentrifuge tube and pro-
cessed for the PCSK9 immunoassay. Meanwhile the cells were
scraped in 40 µL ice-cold lysis buffer (RIPA buffer + inhibitor
cocktail + 1:100 PMSF + 1:100 Na-orthovanadate) and trans-
ferred in an ice-cold microcentrifuge tube. After centrifugation
at 16,060 g for 15 min at 4 °C, the supernatant was recovered
and transferred in a new ice-cold tube.Total proteins were quan-
tified by the Bradford method and 50 µg of total proteins loaded
on a pre-cast 7.5% sodium dodecyl sulphate–polyacrylamide
(SDS-PAGE) gel at 130 V for 45 min. Subsequently, the gel was
transferred to a nitrocellulose membrane (Mini Nitrocellu-
lose Transfer Packs), using a Trans-blot Turbo at 1.3 A, 25 V for
7 min. Target proteins, on milk blocked membrane, were de-
tected by primary antibodies as follows: anti-PCSK9, anti-
HNF1-alpha, and anti-β-actin. Secondary antibodies conjugated
with HRP and a chemiluminescent reagent were used to
visualise target proteins and their signal was quantified using
the Image Lab Software (Bio-Rad). The internal control β-actin
was used to normalise loading variations.
2.6. Quantification of excreted PCSK9 in cell culture
experiments by ELISA
The supernatants collected from HepG2 cells were centri-
fuged at 600 g for 10 min at 4 °C. They were recovered and
diluted with the ratio 1:10 with DMEM in a new ice-cold tube.
PCSK9 was quantified by ELISA (R&D System,Minneapolis, MN,
USA) using the same kit and methodology described above for
the quantification in the plasma of the subjects of the clini-
cal study (Section 2.2).
2.7. Statistically analysis
Statistical analyses were carried out by one-way ANOVA using
the software Prism 6 (GraphPad, La Jolla, CA, USA) followed by
Dunnett’s test. Values were expressed as means ± SEM; p-val-
ues < 0.05 were considered to be significant.
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3. Results
3.1. Lupin protein reduce the plasma levels of PCSK9 in
mild hypercholesterolaemic subjects
The control group (casein bar) and treatment group (lupin
protein bar) of the clinical trial (Sirtori et al., 2012) were com-
posed by 19 and 20 individuals, respectively. For 4 weeks, they
consumed two dietary bars corresponding to a total amount
of 30 g protein per day. The average baseline and final values
of the lipids and PCSK9 plasma levels are reported in Table 1,
whereas HDL-cholesterol and total triglyceride levels re-
mained essentially unchanged in both groups, a significant total
cholesterol reduction (−11.6 mg/dL = −4.2%, p < 0.05) and a small
non-significant LDL-cholesterol one were observed in the lupin
group, but not in the control group. Additionally, a significant
reduction of PCSK9 plasma level was detected in the treat-
ment group, whereas only a very small non-statistically
significant change was observed in the control group. In par-
ticular, when the data were compared by ANOVA with the
Dunnett’s test, followed by adjustment for baseline values, the
reduction of the plasma PCSK9 levels of the lupin group was
equal to 8.5% (p = 0.0454) versus the control group.
3.2. Preparation and analysis of the peptide mixtures
A total protein extract from lupin seed was hydrolysed sepa-
rately with pepsin and trypsin to produce peptic peptides and
tryptic peptides.Analysis by nano LC-MS/MS permitted to iden-
tify more than 2000 peptides in the pepsin digested mixture
and about 3000 in the trypsin digested one (Lammi et al., 2014).
By consulting the Uniprot_viridiplantae database using the
Mascot software, it was possible to assign only a small number
of peptides to known lupin proteins, probably due to the very
incomplete sequencing of lupin proteins. Most peptides belong
to the main lupin storage proteins, by far the most abundant
in the total protein extract as shown by SDS-PAGE.
In the tryptic sample (Table 2a), 12 peptides were assigned
to L. albus vicilin-like protein (Q53HY0), 10 peptides to L. albus
beta-conglutin precursor (Q6EBC1), 4 peptides to Lupinus
angustifolius conglutin beta (B0YJF8)], 4 peptides to L. angustifolius
conglutin-beta (Q53I55)], and 2 to L. albus conglutin-delta seed
storage protein precursor (Q99235). Moreover, two peptides were
assigned to another plant protein, i.e. Zea mays actin partial
(ADF3). In the peptic hydrolysate (Table 2b), 21 peptides were
assigned to L. albus vicilin-like protein (Q53HY0), 18 peptides
to L. albus beta-conglutin (Q6EBC1), 7 peptides to L. angustifolius
conglutin-alpha 3 (F5B8V8], and 8 peptides to L. albus conglutin-
gamma (Q9FSH9).
3.3. Lupin peptides reduce the protein levels of PCSK9
and hepatocyte nuclear factor 1 alpha (HNF1-alpha) in
HepG2 cells
HepG2 cells were treated for 24 h with peptic and tryptic pep-
tides at the concentrations of 1.0–2.5 mg/mL and 0.5–1.0 mg/
mL, respectively. Using immunoblotting technique, two bands
were detected: the former corresponded to the precursor
~75 kDa PCSK9 (PCSK9-P), the latter to the mature ~62 kDa
PCSK9 (PCSK9-M). Immunoblotting experiments showed that
the treatments with both lupin peptide mixtures reduced the
PCSK9 protein levels (Fig. 1). In particular, lupin peptic pep-
tides (1.0 and 2.5 mg/mL) reduce the precursor PCSK9 protein
level by 66% and 58% versus the untreated sample, while tryptic
lupin peptides (0.5 and 1.0 mg/mL) reduce the precursor PCSK9
protein levels by 61% and 53% versus the control, respec-
tively, at each treatment concentration (Fig. 1B).
In the same experiments, also the protein levels of mature
PCSK9-Mweremeasured by immunoblotting. Fig. 1C shows that
both peptic and tryptic peptides are able to decrease the protein
level of PCSK9-M versus the untreated sample. In particular,
at 1.0 and 2.5 mg/mL, respectively, peptic peptides mediate 52%
and 58% reductions of the PCSK9-M protein, whereas, at 0.5
and 1.0 mg/mL, tryptic peptides mediate 61% and 44% de-
creases versus the untreated sample (Fig. 1C).
Both peptic and tryptic peptides affected also the protein
levels of HNF-1 alpha (Fig. 2): peptic peptides decreased it by
28% at 1 mg/mL and 25% at 2.5 mg/mL versus the untreated
sample, whereas the treatment with tryptic peptides led to a
significant 30% reduction of the HNF1-alpha protein produc-
tion at 1.0 mg/mL, but not at 0.5 mg/mL.
3.4. Lupin peptides reduce the secretion of mature PCSK9
by human hepatic HepG2 cells
The same cells were treated with peptic peptides (1.0 and
2.5 mg/mL) and tryptic peptides (0.5 and 1.0 mg/mL) for 24 h.
On the second day, the cell culture medium was collected and
the effects of lupin peptide treatments on the capacity of HepG2
cells to secrete PCSK9-Mwere assessed using the ELISA kit. Fig. 3
clearly indicates that both peptic and tryptic lupin peptides sig-
nificantly reduced the secretion of PCSK9-M by about one third
vs. the untreated samples. More in detail, untreated HepG2 cells
secreted 141 ng/mL of PCSK9-M, whereas after treatment
with peptic lupin peptides (1.0 and 2.5 mg/mL), they secreted
94.3 and 97.3 ng/mL of PCSK9 and, after treatment with tryptic
lupin peptides (1.0 and 0.5 mg/mL), they secreted 94.3 and
93.6 ng/mL PCSK9-M, respectively.
Table 1 – Effect of lupin protein consumption on lipid
parameters and PCSK9 plasma levels in mild
hypercholesterolaemic patients: data are expressed as
mean ± SD.
Parameter Casein Lupin
protein
Total cholesterol (mg/dL)a Baseline 272.4 ± 34.4 274.0 ± 40.0
4 weeks 275.2 ± 26.9 262.4 ± 40.8*
LDL-cholesterol (mg/dL)a Baseline 188.8 ± 36.5 188.2 ± 35.4
4 weeks 193.7 ± 26.7 182.6 ± 40.6
HDL-cholesterol (mg/dL)a Baseline 57.0 ± 12.4 56.0 ± 13.9
4 weeks 57.6 ± 12.8 54.7 ± 15.7
Triglycerides (mg/dL)a Baseline 126.1 ± 45.4 145.6 ± 70.9
4 weeks 115.2 ± 34.6 126.5 ± 59.6
PCSK9 (ng/mL) Baseline 78.8 ± 17.3 82.9 ± 22.2
4 weeks 75.3 ± 14.0 75.9 ± 22.4*
* p < 0.05 vs. baseline.
a Selected data from a previous paper (Sirtori et al., 2012).
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Table 2 – (a) Lupin peptides identified by mass spectrometry in the tryptic hydrolysate. (b) Lupin peptides identified by
mass spectrometry in the peptic hydrolysate.
Accession
number
Protein
name
Mascot
protein
score
Protein
mass
N.
peptides
m/z z Mr Peptide
delta
Ion
score
Peptide sequence
(a)
Q53HY0 Vicilin-like
protein
[Lupinus albus]
969 61994 12 419.35 2 836.40 0.27 40 YEEIQR
1051.58 1 1050.50 0.07 32 SNEPIYSNK
526.62 2 1050.50 0.73 27 SNEPIYSNK
688.15 2 1373.63 0.66 47 YGNFYEITPDR
1463.62 1 1462.69 −0.08 47 ELTFPGSAEDIER
732.62 2 1462.69 0.54 63 ELTFPGSAEDIER
762.62 2 1522.66 0.56 76 EQEQQQGSPSYSR
1557.63 1 1556.79 −0.17 102 HSDADYVLVVLNGR
779.47 2 1556.79 0.12 63 HSDADYVLVVLNGR
791.66 2 1580.75 0.56 61 GQEQSHQDEGVIVR
823.03 2 1643.69 0.35 76 QQDEQEEEPEEVR
863.99 2 1726.00 −0.04 28 IVEFQSKPNTLILPK
576.40 3 1726.00 0.18 48 IVEFQSKPNTLILPK
932.71 2 1863.85 −0.45 94 ILLGNEDEQEYEEQR
840.60 3 2518.31 0.46 33 LSEGDIFVIPAGYPISVNASSNLR
1090.84 3 3268.66 0.83 71 NPQVQDLDISLTFTEINEGALLLPHYNSK
Q6EBC1 Beta-conglutin
precursor
[Lupinus albus]
917 62092 10 419.35 2 836.40 0.27 40 YEEIQR
1051.58 1 1050.50 0.07 32 SNEPIYSNK
526.62 2 1050.50 0.73 27 SNEPIYSNK
688.15 2 1373.63 0.66 47 YGNFYEITPDR
762.62 2 1522.66 0.56 76 EQEQQQGSPSYSR
1557.63 1 1556.79 −0.17 102 HSDADYVLVVLNGR
779.47 2 1556.79 0.12 63 HSDADYVLVVLNGR
1568.69 1 1567.84 −0.16 64 INEGALLLPHYNSK
784.95 2 1567.84 0.05 59 INEGALLLPHYNSK
863.99 2 1726.00 −0.04 28 IVEFQSKPNTLILPK
576.40 3 1726.00 0.18 48 IVEFQSKPNTLILPK
874.70 2 1746.84 0.55 65 AVNELTFPGSAEDIER
932.71 2 1863.85 −0.45 94 IILGNEDEQEYEEQR
1034.78 3 3100.55 0.77 72 YGNFYEITPDRNPQVQDLNISLTYIK
Q99235 Conglutin-
delta seed
storage
protein
precursor
[Lupinus albus]
573 17641 2 687.93 2 1373.61 0.24 60 IQQQEEEEEGR
934.22 2 1866.93 −0.51 56 QEEQLLEQELENLPR
Q53I55 Legumin-like
protein
[Lupinus albus]
399 58830 4 638.61 3 1912.87 −0.06 49 HNIGESTSPDAYNPQAGR
957.68 2 1912.87 0.47 78 HNIGESTSPDAYNPQAGR
966.12 2 1929.75 0.48 102 HGREEEEEEEEEDER
1264.26 2 2526.22 0.29 66 LNALEPDNTVQSEAGTIETWNPK
843.21 3 2526.22 0.37 21 LNALEPDNTVQSEAGTIETWNPK
1591.41 2 3180.45 0.35 100 EGGQGQQQEGGNVLSGFDDEFLEEALSVNK
1061.44 3 3180.45 0.84 27 EGGQGQQQEGGNVLSGFDDEFLEEALSVNK
B0YJF8 Conglutin-beta
[Lupinus
angustifolius]
115 61490 4 419.35 2 836.40 0.27 40 YEEIQR
611.40 3 1831.78 −0.61 21 QQDEQEEEEEEVRR
840.60 3 2518.31 0.46 33 LSEGDIFVIPAGYPISVNASSNLR
1090.84 3 3268.66 0.83 71 NPQVQDLDISLTFTEINEGALLLPHYNSK
ADF3 Actin, partial
[Zea mays]
90 37282 2 874.37 2 1746.88 −0.16 90 SYELPDGQVITIGAER
652.78 3 1955.04 0.28 27 VAPEEHPTLLTEAPLNPK
(b)
Q53HY0 Vicilin-like
protein
[Lupinus albus]
434 61994 21 667.23 1 666.29 −0.07 39 SEGDIF
695.29 1 694.35 −0.07 32 DISLTF
415.56 2 828.38 0.73 44 SNKYGNF
958.32 1 957.49 −0.18 21 AIPINNPGY
505.05 2 1007.50 0.59 32 IKNQQQSY
1105.36 1 1104.56 −0.21 31 AIPINNPGYF
553.34 2 1104.56 0.11 49 AIPINNPGYF
578.54 2 1154.57 0.50 32 IKNQQQSYF
1169.52 1 1168.61 −0.10 36 ILNPDDNQKL
595.27 2 1188.63 −0.10 25 LPHYNSKAIF
1189.58 1 1188.63 −0.06 38 LPHYNSKAIF
651.77 2 1301.71 −0.19 27 LLPHYNSKAIF
652.33 2 1302.57 0.08 62 YPSSTKDQQSY
454.46 3 1359.69 0.66 35 SRRQRNPYHF
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4. Discussion
In recent years, many studies have extensively improved our
understanding of the (patho)physiological role of PCSK9 in
human biology (Giunzioni & Tavori, 2015; Gu & Zhang, 2015;
Lambert et al., 2012). PCSK9 plays a pivotal role in the regu-
lation of the LDLR activity on the hepatic cell surface, because
it promotes its degradation and prevents its recycling to the
cell membrane. Consequently, it has become a novel target for
lipid-lowering therapy and numerous pharmacological ap-
proaches to inhibit PCSK9 function are currently under
investigation. One possibility is the development of agents that
interfere with LDLR binding by targeting PCSK9 in the circu-
lation, as shown with several monoclonal antibodies (Koren
et al., 2012), small peptides (Shan et al., 2008; Zhang et al., 2014),
and adnectins.Very recently, the American Food and Drug Ad-
ministration has approved themonoclonal antibody evolocumab
(Shantha & Robinson, 2015), for the treatment of patients who
are unable to keep their LDL-C under control with current treat-
ment options. A second approach is to reduce hepatic PCSK9
synthesis through gene silencing with small interfering RNA
(siRNA) or antisense oligonucleotides (Fitzgerald et al., 2014;
Lindholm et al., 2012). The third approach, which has not
reached clinical development yet, involves inhibition of PCSK9
production by targeting its intracellular processing (Lambert
et al., 2012).
Berberine is a naturally occurring alkaloid with cholesterol-
lowering properties, present in the formulation of Armolipid
andArmolipid Plus (Ruscica et al., 2014), two commercial dietary
supplements. Experimental evidences indicate that berber-
ine decreases the PCSK9 mRNA expression and increases LDLR
in vitro and in animal studies (Cameron et al., 2008; Kong et al.,
2004), through the down-regulation of the HNF1-alpha protein
Table 2 – (continued)
Accession
number
Protein
name
Mascot
protein
score
Protein
mass
N.
peptides
m/z z Mr Peptide
delta
Ion
score
Peptide sequence
681.19 2 1359.69 0.67 32 SRRQRNPYHF
688.58 2 1375.73 −0.60 56 IVVVGEGNGKYEL
725.88 2 1449.64 0.10 44 YPSSTKDQQSYF
763.10 2 1523.76 0.44 43 EITPDRNPQVQDL
518.59 3 1552.91 −0.17 23 RVVKLAIPINNPGY
844.31 2 1686.82 −0.21 32 YEITPDRNPQVQDL
844.72 2 1687.80 −0.38 24 RSNEPIYSNKYGNF
851.24 2 1699.98 0.49 61 RVVKLAIPINNPGYF
865.24 2 1727.73 0.74 47 YDFYPSSTKDQQSY
1114.25 2 2226.09 0.39 120 TKYAQSSSGKDKPSQSGPFNL
Q6EBC1 Beta-conglutin
[Lupinus
albus]
141 62092 18 667.23 1 666.29 −0.07 39 SEGDIF
415.56 2 828.38 0.73 44 SNKYGNF
429.48 2 856.50 0.44 54 IKINEGAL
958.32 1 957.49 −0.18 21 AIPINNPGY
505.05 2 1007.50 0.59 32 IKNQQQSY
1105.36 1 1104.56 −0.21 31 AIPINNPGYF
578.54 2 1154.57 0.50 32 IKNQQQSYF
1169.52 1 1168.61 −0.10 36 ILNPDDNQKL
603.69 2 1204.62 0.73 22 LPHYNSKAIY
652.33 2 1302.57 0.08 62 YPSSTKDQQSY
454.46 3 1359.69 0.66 35 SRRQRNPYHF
725.88 2 1449.64 0.10 44 YPSSTKDQQSYF
763.10 2 1523.76 0.44 43 EITPDRNPQVQDL
518.59 3 1552.91 −0.17 23 RVVKLAIPINNPGY
844.31 2 1686.82 −0.21 32 YEITPDRNPQVQDL
844.72 2 1687.80 −0.38 24 RSNEPIYSNKYGNF
851.24 2 1699.98 0.49 61 RVVKLAIPINNPGYF
865.24 2 1727.73 0.74 47 YDFYPSSTKDQQSY
F5B8V8 Conglutin-
alpha [Lupinus
angustifolius]
73 67683 7 703.36 1 702.37 −0.02 28 VVPQNF
797.22 1 796.34 −0.13 33 SGFDPQF
816.38 1 815.45 −0.09 22 LVVPQNF
854.49 1 853.50 −0.02 21 RGIPAEVL
1029.57 1 1028.53 0.03 23 VIPPGTPYW
639.13 2 1275.61 0.64 24 YRNGIYAPHW
647.15 2 1292.64 −0.36 62 VIPPGTPYWTY
Q9FSH9 Conglutin-
gamma
[Lupinus albus]
50 49872 8 354.39 2 706.34 0.42 36 FSHFGL
719.40 1 718.33 0.07 28 FDLNNP
422.88 2 843.52 0.21 44 VKIPQFL
619.18 2 1235.64 0.70 31 TPLTISKQGEY
633.73 2 1264.69 0.76 35 VDGGVHTRAGIAL
708.72 2 1414.77 0.66 50 DTKKISGGVPSVDL
726.97 2 1451.81 0.11 46 LTQKGLPNNVQGAL
678.14 3 2032.11 −0.71 24 VLPIQQDASTKLHWGNIL
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expression (Dong, Li, Singh, Cao, & Liu, 2015). In a similar way,
curcumin suppression of PCSK9 expression is associated with
increases in cell-surface LDLR expression and activity in HepG2
cells as well as a reduction of nuclear abundance of HNF1-
alpha,with a distinct molecular mechanism compared to statins
(Tai et al., 2014).
Up to now, the most common pharmacological strategy for
the treatment of hypercholesterolaemia is based on statins,
which function by inhibiting HMGCoAR, the rate-limiting
enzyme in cholesterol synthesis, thereby elevating the LDLR
expression to increase the LDL particle uptake from the cir-
culation (Goldstein & Brown, 2009). However, some patients are
insensitive to statin treatment or experience serious adverse
effects (Pirillo & Catapano, 2015). Furthermore, statins in-
crease the expression of PCSK9 (Awan et al., 2012), thereby
counteracting their beneficial effects.
Using HepG2 cells, we have recently demonstrated that
the hypocholesterolaemic effects of peptides deriving from
the hydrolysis of lupin protein are based on the inhibition of
HMGCoAR activity (Lammi et al., 2014). Similar to statins, the
consequent reduction of intracellular cholesterol levels leads
to SREBP-2 activation, which in turn increases the expression
of LDLR. The consequent improved LDLR activity leads to an
enhanced ability of HepG2 cells to uptake extracellular LDL
with a final hypocholesterolaemic effect. In this context, this
study represents a major innovation, since it provides either
clinical indications that a lupin diet decreases the plasma
levels of PCSK9 or in vitro evidences that lupin peptides may
positively influence intracellular PCSK9 processing in
hepatocytes.
Fig. 1 – Effects of peptic and tryptic lupin peptides on
PCSK9 protein levels. HepG2 cells (1.5 × 105) were treated
with 1.0 and 2.5 mg/mL of peptic peptides (P) and 0.5 and
1.0 mg/mL of tryptic peptides (T) for 24 h. PCSK9 and
β-actin immunoblotting signals were detected using
specific anti-PCSK9 and anti-β-actin primary antibodies,
respectively. PCSK9-P and PCSK9-M represent the
proprotein and the cleaved mature form of PCSK9,
respectively (A). PCSK9-P (B) and PCSK9-M (C) signals were
quantified by ImageLab software (Bio-Rad) and normalised
with β-actin signals. Bars represent averages of duplicate
samples ± SEM of three independent experiments.
*p < 0.05, **p < 0.001 and ***p < 0.0001 versus untreated
sample (C).
Fig. 2 – Effects of peptic (P) and tryptic (T) lupin peptides on
HNF1-alpha protein levels. HepG2 cells (1.5 × 105) were
treated with 1.0 and 2.5 mg/mL of peptic peptides (P) and
0.5 and 1 mg/mL of tryptic peptides (T) for 24 h. HNF1-
alpha and β-actin immunoblotting signals were detected
using specific anti-HNF1-alpha and anti-β-actin primary
antibodies, respectively. HNF1-alpha signals (A) were
quantified by ImageLab software (Bio-Rad) and normalised
with β-actin signals. Bars represent averages of duplicate
samples ± SEM of three independent experiments (B).
*p < 0.05 versus untreated sample (C).
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To the best of our knowledge, this is the first study showing
that the consumption of lupin protein (30 g/day) decreases the
plasma PCSK9 levels in moderately hypercholesterolaemic in-
dividuals. This means that the potential health benefits of
consuming lupin protein may derive not only from the reduc-
tion of total cholesterol and LDL-cholesterol (Bähr et al., 2015;
Sirtori et al., 2012), but also from the decrease of the PCSK9
plasma levels. This fact is very relevant, since PCSK9 plasma
levels correlates with the incidence of cardiovascular disease
(CVD) events in humans (Shantha & Robinson, 2015) and are
predictive of recurrent clinical events in patients with stable
CVD treated with low-dose atorvastatin (Ridker, Rifai, Bradwin,
& Rose, 2016).
Furthermore, this work has elucidated some relevant dif-
ferences between the mechanism of action of lupin and statins.
In fact, although lupin peptides apparently inhibit the activ-
ity of HMGCoAR as statins (Lammi et al., 2014), surprisingly
they do not increase the plasma level of PCSK9 (Table 1), a main
drawback of statins.
An important aspect of the PCSK9-LDLR pathway in me-
diating LDL clearance is that their transcription is coordinately
regulated by sterols through a common SRE motif embedded
in their gene promoters and is co-induced by current choles-
terol lowering drugs, such as statins, through activation of
SREBPs (Dubuc et al., 2004; Horton et al., 2003; Jeong et al.,
2008). Statin treatment increases the transcription of both
LDLR and PCSK9 (Dubuc et al., 2004). This undesirable
inducing effect of statins on PCSK9 transcription is increas-
ingly recognised as a major limitation to their therapeutic
efficacy in further lowering plasma LDL-C.While in a preced-
ing paper (Lammi et al., 2014) we have demonstrated that
either peptic or tryptic peptides from lupin protein increase
the LDLR protein levels and activity through the up-
regulation of SREBP-2, here we show that the same peptides
also reduce the 692-amino acid precursor (~75 kDa) PCSK9
protein levels with the consequence of a reduction of the
mature enzyme (~62 kDa) (Fig. 1).
A general picture of the molecular mechanism through
which lupin peptides may induce the cholesterol-lowering
effect in hepatocytes is schematically shown in Fig. 4. Pro-
PCSK9 undergoes autocatalytic intramolecular processing
between the Q152 and S153 residues in the endoplasmic
reticulum to form the mature enzyme (Benjannet et al., 2004).
The cleavage of the prodomain is required for PCSK9 matu-
ration and secretion (Li et al., 2007; McNutt et al., 2007). In
agreement with this consideration and with our clinical results,
our findings suggest that the lupin peptide treatment affects
the secretion of mature PCSK9 in the culture medium of
HepG2 cells (Fig. 3). In order to elucidate the mechanism of
action through which lupin peptides positively affect the LDLR
pathway reducing the PCSK9 protein levels and secretion, a
crucial aspect is the regulation of PCSK9 transcription. In
particular, several transcription factors, such as SREBPs and
HNF-1, have been identified as transcriptional activators of
PCSK9 gene expression (Dong et al., 2010; Horton et al., 2003;
Li et al., 2009). PCSK9 and LDLR both contain functional sterol
regulatory elements (SREs) in their promoters that respond
to change in intracellular cholesterol levels through the acti-
vation of the SREBP pathway (Dubuc et al., 2004; Maxwell,
Soccio, Duncan, Sehayek, & Breslow, 2003). However, since
the HNF1 binding site is unique to the PCSK9 promoter and
is not present in the LDLR promoter, modulations of PCSK9
transcription through HNF1 sequence will not affect LDLR
gene expression. Thus, the HNF1 binding site represents a
divergent point to disconnect the co-regulation of PCSK9 with
LDLR and other SREBP target genes (Dong et al., 2015). Indeed,
in this study, we have shown that cholesterol-lowering lupin
peptides decrease hepatic PCSK9 and secreted PCSK9 concen-
trations without affecting LDLR protein levels and other SREBP-2
target genes (such as HMGCoAR) and also the down-
regulation of HNF1-alpha protein content in HepG2 cells has
been observed (Fig. 2).
For the first time, this investigation provides evidence
that the inhibition of PCSK9 production and secretion is a
key effect of lupin protein, which contributes to its
hypocholesterolaemic property. Furthermore, in the frame-
work of a research aimed at a deep comprehension of the
hypocholesterolaemic mechanism of action of lupin protein,
these findings help in explaining the beneficial effects ob-
served in the human study, since also a significant reduction
of plasma PCSK9 levels has been observed (Sirtori et al.,
2012). Our results provide new scientific evidences support-
ing the use of lupin protein as an ingredient for developing
innovative functional foods and open a new area of research
on plant proteins in general (Braithwaite et al., 2014;
Girgih et al., 2014; Patten, Abeywardena, Head, & Bennett,
2012).
Fig. 3 – Analysis of secreted PCSK9 levels by HepG2 cells
after peptic and tryptic lupin peptide treatments. HepG2
cells (1.5 × 105) were treated with 1.0 and 2.5 mg/mL of
peptic peptides (P) and 0.5 and 1.0 mg/mL of tryptic
peptides (T) for 24 h. After each treatment, the medium
was collected and the secreted PCSK9 levels were
measured by ELISA. This assay employs the quantitative
sandwich enzyme immunoassay techniques. A calibration
curve was built using a recombinant human PCSK9. The
absorbance of each reaction was measured at 450 nm
using the Synergy H1 fluorescent plate reader from BioTek.
Data points represent averages ± SEM of three independent
experiments in duplicate. ***p < 0.0001 versus untreated
sample (C).
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